Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Exp Immunol. 1994 Jul;97 Suppl 1:21-4.

The use of intravenous immune globulin in multiple myeloma.

Author information

  • 1Department of Immunology, John Radcliffe Hospital, Oxford, UK.

Abstract

Patients with multiple myeloma suffer from serious bacterial infections throughout the course of the disease. This is probably associated with reduced polyclonal immunoglobulin synthesis. Prophylactic intravenous immune globulin (IVIG) reduces the incidence and recurrence of these infections in the stable phase of the disease. Infections at times of induction chemotherapy and/or relapse have a wider range of causative organisms. Such susceptibility may be associated with abnormal phagocytic function following chemotherapy.

PMID:
8033429
[PubMed - indexed for MEDLINE]
PMCID:
PMC1550368
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk